Company Profile
ResMed Pty Ltd is an Australia-based manufacturer of sleep and respiratory care devices, headquartered in Bella Vista, New South Wales, Australia. Founded in 1989 by Dr. Peter Farrell, the company operates as a core subsidiary of ResMed Inc. (NYSE: RMD / ASX: RMD), serving global sleep and breathing health markets in over 140 countries.
Core Products ＆ Technologies
Sleep ＆ Breathing Devices
• AirSense 10 / AirSense 11: AutoSet CPAP and APAP devices with integrated cellular connectivity and myAir patient engagement
• AirCurve / Lumis: BiLevel and non-invasive ventilation devices for complex sleep apnea and respiratory insufficiency
• AirMini: Portable travel CPAP with waterless humidification
Masks ＆ Patient Interfaces
• AirFit Series: Nasal pillows, nasal masks, and full-face masks with QuietAir venting technology
• AirTouch Series: Memory foam cushion masks for enhanced comfort and seal performance
Digital Health ＆ Software
• AirView: Cloud-based remote patient monitoring platform for clinicians
• Brightree / MatrixCare: Residential care software solutions for out-of-hospital care management
Market Position ＆ Certifications
ResMed holds a global leadership position in the sleep apnea therapy and respiratory devices market, competing with Philips Respironics and Fisher ＆ Paykel Healthcare. Key strengths include:
• 37 years of Australian engineering heritage in positive airway pressure technology
• Digital health ecosystem: Integrated cloud platforms connecting devices, patients, and providers
• Regulatory compliance: FDA cleared, CE marked, TGA registered, and approved by major global health authorities
• Global manufacturing network: Production and R＆D facilities across Australia, Singapore, Malaysia, and the United States
Corporate Timeline
1989 — Founded in Sydney, Australia, as ResMed Holdings Pty Ltd to acquire CPAP technology from Baxter
1994 — ResMed Inc. formed as the ultimate Delaware holding company for global operations
1995 — Completed IPO on NASDAQ; commenced global expansion
1999 — Transferred primary listing to NYSE (RMD) and established ASX secondary listing
2026 — Announced acquisition of Noctrix Health to expand into wearable RLS therapy
Target Markets ＆ Applications
• Obstructive Sleep Apnea (OSA): CPAP, APAP, and BiLevel devices with connected care solutions
• Chronic Respiratory Disease: Non-invasive ventilation and oxygen therapy for COPD and neuromuscular conditions
• Residential Care Software: Brightree and MatrixCare platforms for skilled nursing and home health agencies
Contact Information
Australian Headquarters
Address: 1 Elizabeth Macarthur Drive, Bella Vista, NSW 2153, Australia
Telephone: +61 2 8884 1000
Email: reception@resmed.com.au
Parent Company
ResMed Inc.
Address: 9001 Spectrum Center Blvd., San Diego, CA 92123, USA
Stock: NYSE: RMD / ASX: RMD
Website: resmed.com
Investor Relations: investor.resmed.com
